Stockscreener 앱 받기
2.54
0.79%
0.02
시간 외 거래:
2.59
0.05
+1.97%
전일 마감가:
$2.52
열려 있는:
$2.52
하루 거래량:
105.75K
Relative Volume:
0.27
시가총액:
$38.40M
수익:
$2.09M
순이익/손실:
$-30.04M
주가수익비율:
-0.7771
EPS:
-3.2685
순현금흐름:
$-27.57M
1주 성능:
+4.53%
1개월 성능:
-4.15%
6개월 성능:
-37.13%
1년 성능:
-67.52%
1일 변동 폭
$2.52
$2.63
1주일 범위
$2.41
$2.63
52주 변동 폭
$2.13
$10.00
Cervomed Inc Stock (CRVO) Company Profile
명칭
Cervomed Inc
전화
(617) 744-4400
주소
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
2.54 | 38.40M | 2.09M | -30.04M | -27.57M | -3.2685 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-03-13 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2024-12-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Chardan Capital Markets | Buy → Neutral |
| 2024-12-11 | 다운그레이드 | Morgan Stanley | Overweight → Underweight |
| 2024-12-10 | 다운그레이드 | D. Boral Capital | Buy → Hold |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-12-05 | 개시 | H.C. Wainwright | Buy |
| 2024-09-18 | 개시 | Chardan Capital Markets | Buy |
| 2024-07-26 | 개시 | Morgan Stanley | Overweight |
| 2024-02-15 | 개시 | Canaccord Genuity | Buy |
| 2020-11-17 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2018-03-21 | 개시 | H.C. Wainwright | Buy |
모두보기
Cervomed Inc 주식(CRVO)의 최신 뉴스
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference - The Manila Times
A neuroscience panel in New York will include CervoMed management Sept. 29 - Stock Titan
CervoMed (CRVO) Rallies +1.02% as Bulls Target $2.60 2026-09-16Turnaround Stocks - careplusvn.com
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally - Stocktwits
CervoMed at Cantor healthcare conference: phase iii path in focus By Investing.com - Investing.com Canada
CervoMed at Cantor healthcare conference: phase iii path in focus - Investing.com India
CRVO: Phase III-ready DLB therapy neflamapimod shows strong efficacy and biomarker support - TradingView
Cervomed Inc (CRVO-Q) Stock Price and News - The Globe and Mail
CervoMed highlights late-breaking neflamapimod Phase 2a data - TipRanks
CervoMed (NASDAQ: CRVO) data accepted for late-breaking dementia conference talk - Stock Titan
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting By Investing.com - Investing.com Nigeria
CervoMed to present neflamapimod trial data at ISFTD - grafa.com
CervoMed to present nfvPPA trial biomarker data at ISFTD meeting - Investing.com
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026 - The Manila Times
No approved treatments exist in the U.S. or EU for this dementia type. CervoMed will present trial data. - Stock Titan
CervoMed's neflamapimod wins UK ILAP Innovation Passport for DLB - scanx.trade
CervoMed to Participate in September Investor Conferences - Yahoo! Finance Canada
Price to earnings forward of CervoMed Inc. – NASDAQ:CRVO - TradingView
CRVO News | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed (CRVO) Edges Lower to $2.62 as Shares Press Against Heavy SupportBPI Reversal - dars.gov.et
CervoMed Company Profile & Introduction - Moomoo
Hedge Fund Armistice Sues Drugmaker, Insiders for Stock Dilution - Bloomberg Law News
CervoMed (CRVO) Results Review: EPS Exceeds Its Estimate in the Latest Session; Price Reaction - dars.gov.et
ARMISTICE CAPITAL, LLC Acquires New Stake in CervoMed Inc (CRVO) - GuruFocus
Roth MKM Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $7 - Moomoo
SABBY MANAGEMENT, LLC's CervoMed Inc(CRVO) Holding History - GuruFocus
CRVO Q2 2026 Earnings: Loss Narrows 27.7% vs Estimates, Shares Dip 6.8%Earnings Cycle Outlook - vinanet.vn
CervoMed (CRVO): RA Capital discloses 8.6% stake through 1.27M warrant shares - Stock Titan
CervoMed (CRVO) holders CVI and Heights report 0% stake in amended filing - Stock Titan
Woodline Partners (CRVO) discloses 5.1% beneficial stake in CervoMed common stock - Stock Titan
Armistice Capital discloses 9.53% CervoMed (CRVO) ownership via Master Fund - Stock Titan
CRVO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.64 Beats Estimates by 27.7%; Shares Slip 4.56% - vinanet.vn
CRVO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $18 - Moomoo
CervoMed at Canaccord Genuity conference: dLB push gains ground By Investing.com - Investing.com Nigeria
CRVO: Phase III-ready DLB drug shows strong clinical data; pipeline expands into PPA and ALS - TradingView
CervoMed at Canaccord Genuity conference: dLB push gains ground - Investing.com
CervoMed Inc. (CRVO) Surges 9% as Biotech Stock Approaches Key Resistance at $3.28Stop Loss Guidance - dars.gov.et
JonesTrading Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $12 - Moomoo
CervoMed reports Q2 2026: $24.9M cash position, net loss $6.6M; advancing neflamapimod toward Phase 3 - TradingView
CervoMed (NASDAQ: CRVO) details Q2 2026 loss, cash runway and DLB program - Stock Titan
Canaccord cuts CervoMed stock price target on funding uncertainty By Investing.com - Investing.com India
CervoMed presents data on DLB treatment at AAIC 2026 - scanx.trade
CRVO Maintained by Canaccord Genuity -- Price Target Lowered to $18 - GuruFocus
CervoMed Q2 Results: EPS Misses Estimate, Losses Widen YoY - scanx.trade
CervoMed Q2 Results: Net Loss Widens To $6.6M, Seeks DLB Partner - scanx.trade
Canaccord cuts CervoMed stock price target on funding uncertainty - Investing.com
CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - The Manila Times
CervoMed Q2 net loss lower than estimates as costs drop - TradingView
CCORF Maintains CervoMed(CRVO.US) With Buy Rating, Cuts Target Price to $18 - Moomoo
CRVO Q2'26 Earnings: revenue estimate is 50.00K USD - TradingView
Cervomed Inc (CRVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):